Retatrutide has not received MHRA marketing authorisation, so it cannot be legally prescribed through NHS or private routes in the UK
Keywords , metabolic dysfunction-associated steatohepatitis , incretin therapy , glucagon-like peptide-1 , glucose-dependent insulinotropic polypeptide , glucagon receptor agonism 0 1 INTRODUCTION Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined by hepatic steatosis, characterized by triglyceride accumulation in more than 5% of hepatocytes, alongside any cardiometabolic risk factor establishes a diagnosis of MASLD [1]
View image online ( GLP-1 A three-year retrospective study found patients with polycythemia vera (PV) or myelodysplastic syndromes (MDS) who received GLP-1 RA medications fared better than their peers
doi: 10.1159/000490808 43 TangC.MaZ.ZhuJ.LiuZ.LiuY.LiuY.et al
When to Expect Results Typical patient timeline: Improved glow & hydration: 24 weeks Skin tightening & texture improvement: 48 weeks Hair growth stimulation: 612 weeks Maximal collagen remodeling: 12+ weeks Deep regenerative benefits: ~90 days GHK-Cu delivers both immediate cosmetic benefits and long-term cellular repair